title: Marked bone marrow eosinophilia at the time of relapse of acute myeloblastic leukaemia in association with the appearance of translocation t(12;20)(q24;q11).
abstract: We report a case of acute myeloblastic leukaemia (AML), FAB type M2, with karyotype t(8;21)(q22;q22), who at the time of relapse showed marked eosinophilia of the bone marrow. Karyotype analysis showed the appearance of an additional clone t(8;21)(q22;q22),t(12;20)(q24;q11). To the best of our knowledge, marked eosinophilia has not been reported in association with this particular chromosomal translocation.
authors.affiliation: Haematology Department, George Eliot Hospital, Nuneaton, England.
authors.forename: F
authors.initials: F
authors.lastname: Partridge
authors.forename: W
authors.initials: W
authors.lastname: Richardson
authors.forename: P
authors.initials: P
authors.lastname: Kearns
authors.forename: R
authors.initials: R
authors.lastname: Wilcox
authors.forename: G
authors.initials: G
authors.lastname: Majumdar
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology*; D002881:Chromosomes, Human, Pair 12 / Q000648:ultrastructure*; D002890:Chromosomes, Human, Pair 20 / Q000648:ultrastructure*; D002891:Chromosomes, Human, Pair 21 / Q000648:ultrastructure; D002898:Chromosomes, Human, Pair 8 / Q000648:ultrastructure; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004802:Eosinophilia / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008297:Male; D009364:Neoplasm Recurrence, Local; D012074:Remission Induction; D014178:Translocation, Genetic
chemical_list: D003561:Cytarabine; D005047:Etoposide; D015255:Idarubicin; D003630:Daunorubicin